Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled date : 2021 - 03 - 25 save search
Aspira Women’s Health, Inc. Announces an Agreement for the Development and Commercialization of an Early-Detection Test for Identification of Ovarian Cancer
Published: 2021-03-25 (Crawled : 20:00) - vermillion.com
AWH | $3.48 2.66% 2.59% 10K
|
Health Technology
|
| O: 15.5%
H: 2.58%
C: -12.13%
commercialization test women cancer ovarian cancer
Israeli FemTech Company MobileODT, Engaged in Large Scale Government Cervical Cancer Screening Project
Published: 2021-03-25 (Crawled : 19:00) - biospace.com/
PKX | $68.54 -2.1% -0.07% 180K
|
Non-Energy Minerals
|
| O: 0.03%
H: 0.81%
C: 0.52%
israel cancer leo mobile
Portage Biotech Highlights Initiation of the Invincible Trial, a Phase 2 Early Stage Breast Cancer Study from Intensity Therapeutics
Published: 2021-03-25 (Crawled : 15:15) - biospace.com/
PRTG | $0.2297 -32.44% -48.02% 280K
|
Mining, Quarrying, and Oil and ...
|
| O: 3.59%
H: 0.0%
C: -3.4%
phase 2 cancer biotech iot breast cancer trial
Medicenna Announces Preclinical Data on MDNA11 with Anti-PD-1 Therapy and Unveils Novel Bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit
Published: 2021-03-25 (Crawled : 12:00) - biospace.com/
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
|
| O: 7.05%
H: 0.0%
C: -1.95%
therapy cancer immunotherapy preclinical pre-clinical
Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer
Published: 2021-03-25 (Crawled : 12:00) - biospace.com/
PFE A | $25.69 -0.85% 0.1% 29M
|
Health Technology
|
| O: 0.11%
H: 0.39%
C: 0.06%
therapy cancer breast cancer her2+ her2- her2 metastatic breast cancer
G1 Therapeutics’ COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology
Published: 2021-03-25 (Crawled : 11:00) - globenewswire.com
GTHX | $4.08 -5.34% -5.64% 570K
|
Health Technology
|
| O: -3.28%
H: 17.86%
C: 17.45%
cancer trilaciclib
484MH, Senior Scientist / Scientist, Cancer Immunotherapy
Published: 2021-03-25 (Crawled : 01:00) - fatetherapeutics.com
FATE | $5.39 -4.43% -4.64% 2.8M
|
Health Technology
|
| O: -6.07%
H: 2.81%
C: 1.97%
immunotherapy therapy cancer
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.